$26.36
00.00%
Pre-Market: Jul 19, 4:03 PM EDT
15 minutes delayed
Comments
Loading...
Dentsply Sirona
XRAYNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Dentsply Sirona (NASDAQ:XRAY) Stock, Analyst Ratings, Price Targets, Forecasts
Dentsply Sirona Inc has a consensus price target of $41.64 based on the ratings of 16 analysts. The high is $67 issued by Credit Suisse on March 1, 2022. The low is $27 issued by Evercore ISI Group on July 9, 2024. The 3 most-recent analyst ratings were released by Stifel, Evercore ISI Group, and Barrington Research on July 18, 2024, July 9, 2024, and July 8, 2024, respectively. With an average price target of $31 between Stifel, Evercore ISI Group, and Barrington Research, there's an implied 17.60% upside for Dentsply Sirona Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Evercore ISI Group
Barrington Research
Goldman Sachs
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Dentsply Sirona
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/18/2024 | Buy Now | 6.22% | Stifel | Jonathan Block | $30 → $28 | Maintains | Hold | Get Alert |
| 07/09/2024 | Buy Now | 2.43% | Evercore ISI Group | Elizabeth Anderson | $28 → $27 | Maintains | Outperform | Get Alert |
| 07/08/2024 | Buy Now | 44.16% | Barrington Research | Michael Petusky | $38 → $38 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | 6.22% | Evercore ISI Group | Elizabeth Anderson | $35 → $28 | Maintains | Outperform | Get Alert |
| 05/06/2024 | Buy Now | 13.81% | Goldman Sachs | Nathan Rich | $34 → $30 | Maintains | Neutral | Get Alert |
| 05/03/2024 | Buy Now | 32.78% | Evercore ISI Group | Elizabeth Anderson | $40 → $35 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 44.16% | Barrington Research | Michael Petusky | $41 → $38 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 21.4% | Piper Sandler | Jason Bednar | $35 → $32 | Reiterates | Neutral → Neutral | Get Alert |
| 05/03/2024 | Buy Now | 25.19% | Baird | Jeffrey Johnson | $35 → $33 | Maintains | Neutral | Get Alert |
| 05/03/2024 | Buy Now | 36.57% | Needham | David Saxon | $42 → $36 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 55.54% | Barrington Research | Michael Petusky | $41 → $41 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 55.54% | Barrington Research | Michael Petusky | → $41 | Reiterates | Outperform → Outperform | Get Alert |
| 02/29/2024 | Buy Now | 59.33% | Needham | David Saxon | → $42 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | 59.33% | Leerink Partners | Michael Cherny | → $42 | Initiates | → Outperform | Get Alert |
| 01/12/2024 | Buy Now | 32.78% | Piper Sandler | Jason Bednar | $31 → $35 | Maintains | Neutral | Get Alert |
| 01/09/2024 | Buy Now | 59.33% | Needham | David Saxon | $35 → $42 | Maintains | Buy | Get Alert |
| 11/16/2023 | Buy Now | 32.78% | Needham | David Saxon | → $35 | Initiates | → Buy | Get Alert |
| 11/13/2023 | Buy Now | 21.4% | Stifel | Jonathan Block | $35 → $32 | Maintains | Hold | Get Alert |
| 11/10/2023 | Buy Now | — | William Blair | Brandon Vazquez | — | Upgrade | Market Perform → Outperform | Get Alert |
| 11/07/2023 | Buy Now | 36.57% | Goldman Sachs | Nathan Rich | $42 → $36 | Maintains | Neutral | Get Alert |
| 11/03/2023 | Buy Now | 55.54% | Barrington Research | Michael Petusky | $51 → $41 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 47.95% | Morgan Stanley | Erin Wright | $43 → $39 | Maintains | Overweight | Get Alert |
| 11/01/2023 | Buy Now | 32.78% | Stifel | Jonathan Block | $41 → $35 | Maintains | Hold | Get Alert |
| 10/20/2023 | Buy Now | 63.13% | Morgan Stanley | Erin Wright | $47 → $43 | Maintains | Overweight | Get Alert |
| 09/22/2023 | Buy Now | 47.95% | Piper Sandler | Jason Bednar | $42 → $39 | Maintains | Neutral | Get Alert |
| 08/04/2023 | Buy Now | 93.47% | Barrington Research | Michael Petusky | → $51 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 93.47% | Barrington Research | Michael Petusky | $43 → $51 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 55.54% | Stifel | Jonathan Block | $37 → $41 | Maintains | Hold | Get Alert |
| 05/04/2023 | Buy Now | 78.3% | Morgan Stanley | Erin Wright | $45 → $47 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | 74.51% | Baird | Jeffrey Johnson | $36 → $46 | Maintains | Neutral | Get Alert |
| 04/19/2023 | Buy Now | 70.71% | Morgan Stanley | Erin Wright | $39 → $45 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 47.95% | Goldman Sachs | Nathan Rich | $34 → $39 | Maintains | Neutral | Get Alert |
| 03/01/2023 | Buy Now | 47.95% | Goldman Sachs | Nathan Rich | $34 → $39 | Maintains | Neutral | Get Alert |
| 02/06/2023 | Buy Now | 32.78% | Piper Sandler | Jason Bednar | $29 → $35 | Maintains | Neutral | Get Alert |
| 01/12/2023 | Buy Now | — | William Blair | Brandon Vazquez | — | Upgrade | Underperform → Market Perform | Get Alert |
| 11/16/2022 | Buy Now | 28.98% | Goldman Sachs | Nathan Rich | $41 → $34 | Maintains | Neutral | Get Alert |
| 11/15/2022 | Buy Now | 47.95% | Morgan Stanley | Erin Wright | $42 → $39 | Maintains | Overweight | Get Alert |
| 10/13/2022 | Buy Now | 59.33% | Morgan Stanley | Erin Wright | $44 → $42 | Maintains | Overweight | Get Alert |
| 08/05/2022 | Buy Now | — | William Blair | John Kreger | — | Downgrade | Market Perform → Underperform | Get Alert |
| 07/21/2022 | Buy Now | 55.54% | Goldman Sachs | Nathan Rich | $42 → $41 | Maintains | Neutral | Get Alert |
| 07/20/2022 | Buy Now | 66.92% | Morgan Stanley | Erin Wright | $48 → $44 | Maintains | Overweight | Get Alert |
| 06/02/2022 | Buy Now | 78.3% | UBS | Kevin Caliendo | $58 → $47 | Upgrade | Neutral → Buy | Get Alert |
| 05/11/2022 | Buy Now | 82.09% | Morgan Stanley | Erin Wright | $52 → $48 | Maintains | Overweight | Get Alert |
| 04/22/2022 | Buy Now | 82.09% | HC Wainwright & Co. | Yi Chen | $58 → $48 | Maintains | Neutral | Get Alert |
| 04/21/2022 | Buy Now | 78.3% | Goldman Sachs | Nathan Rich | $59 → $47 | Maintains | Neutral | Get Alert |
| 04/20/2022 | Buy Now | 97.27% | Morgan Stanley | Erin Wright | $62 → $52 | Maintains | Overweight | Get Alert |
| 04/20/2022 | Buy Now | 85.89% | B of A Securities | Michael Cherny | $66 → $49 | Downgrade | Buy → Neutral | Get Alert |
| 04/20/2022 | Buy Now | 74.51% | Piper Sandler | Jason Bednar | $71 → $46 | Downgrade | Overweight → Neutral | Get Alert |
| 04/19/2022 | Buy Now | — | William Blair | John Kreger | — | Downgrade | Outperform → Market Perform | Get Alert |
| 04/19/2022 | Buy Now | 82.09% | Baird | Jeffrey Johnson | → $48 | Downgrade | Outperform → Neutral | Get Alert |
| 04/19/2022 | Buy Now | — | B of A Securities | Michael Cherny | — | Downgrade | Buy → Neutral | Get Alert |
| 03/01/2022 | Buy Now | 123.82% | Goldman Sachs | Nathan Rich | $66 → $59 | Maintains | Neutral | Get Alert |
| 03/01/2022 | Buy Now | 154.17% | Credit Suisse | Matt Miksic | $68 → $67 | Maintains | Outperform | Get Alert |
| 02/18/2022 | Buy Now | 154.17% | Baird | Jeff Johnson | $78 → $67 | Maintains | Outperform | Get Alert |
| 01/31/2022 | Buy Now | 135.2% | Morgan Stanley | Erin Wright | → $62 | Initiates | → Overweight | Get Alert |
| 08/09/2021 | Buy Now | 150.38% | HC Wainwright & Co. | Yi Chen | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Dentsply Sirona (XRAY) stock?
The latest price target for Dentsply Sirona (NASDAQ:XRAY) was reported by Stifel on July 18, 2024. The analyst firm set a price target for $28.00 expecting XRAY to rise to within 12 months (a possible 6.22% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dentsply Sirona (XRAY)?
The latest analyst rating for Dentsply Sirona (NASDAQ:XRAY) was provided by Stifel, and Dentsply Sirona maintained their hold rating.
When was the last upgrade for Dentsply Sirona (XRAY)?
The last upgrade for Dentsply Sirona Inc happened on November 10, 2023 when William Blair raised their price target to N/A. William Blair previously had a market perform for Dentsply Sirona Inc.
When was the last downgrade for Dentsply Sirona (XRAY)?
The last downgrade for Dentsply Sirona Inc happened on August 5, 2022 when William Blair changed their price target from N/A to N/A for Dentsply Sirona Inc.
When is the next analyst rating going to be posted or updated for Dentsply Sirona (XRAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dentsply Sirona, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dentsply Sirona was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.
Is the Analyst Rating Dentsply Sirona (XRAY) correct?
While ratings are subjective and will change, the latest Dentsply Sirona (XRAY) rating was a maintained with a price target of $30.00 to $28.00. The current price Dentsply Sirona (XRAY) is trading at is $26.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.